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Abstract  
Antimalarials can interact with heme covalently, by - interactions or hydrogen bonding. 
Consequently, the prototropy of 4-aminoquinolines and quinoline methanols was investigated 
using quantum mechanics. Calculations showed mefloquine protonated preferentially at the 
piperidine and was impeded at the endocyclic nitrogen due to electronic rather than steric 
factors. In gas phase calculations, 7-substituted mono- and bis-4-aminoquinolines were 
preferentially protonated at the endocyclic quinoline nitrogen. By contrast, compounds with a 
trifluoromethyl substituent on both the 2- and 8-positions, reversed the order of protonation 
which now favored the exocyclic secondary amine nitrogen at the 4-position. Loss of 
antimalarial efficacy by CF3 groups simultaneously occupying the 2- and 8-positions was 
recovered if the CF3 group occupied the 7-position. Hence, trifluromethyl groups buttressing 
quinolinyl nitrogen shifted binding of antimalarials to hematin, enabling switching from 
endocyclic to the exocyclic N. Both theoretical calculations (DFT calculations: B3LYP/6-
31+G*) and crystal structure of (±)-trans-N1,N2-bis-(2,8-ditrifluoromethylquinolin-4-
yl)cyclohexane-1,2-diamine were used to reveal preferred mode(s) of interaction with 
hematin. The order of antimalarial activity in vivo followed the capacity for a redox change of 
the iron(III)state which has important implications for the future rational design of 4-
aminoquinoline antimalarials. 
 
KEYWORDS: trifluorinated antimalarials, drug-receptor, pharmacology, X-ray 
crystallography, DFT modelling, bisquinolines, NMR, EPR 
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Introduction 
It is unlikely that an effective and affordable antimalarial vaccine will become 
available in the near future for widespread use; therefore, antimalarial drugs will continue to 
be important in the management and treatment of malaria. One currently effective, but 
expensive, antimalarial drug is the fluorinated quinoline methanol, mefloquine 1 [LariamTM, 
(R, S)-(±)-α-2-piperidinyl-2,8-(bis-trifluoromethyl)-4-quinolinyl methanol]. Despite limited 
clinical use, the incidence of drug resistance to 1a continues to increase worldwide. Also of 
great concern, especially to travelers from wealthy non-endemic countries, is the occurrence 
of adverse neuropsychiatric reactions to 1a.[1] It is imperative, therefore, to construct 
congeners of existing antimalarials, as well as identifying new drug leads in order to provide 
a range of selectively toxic, clinically useful antimalarial agents and to determine the 
molecular mechanism(s) of antimalarial action. Our research in this area has led to the 
characterization of a putative bisquinoline receptor encoded with desirable features within 4-
aminoquinolines and, perhaps, quinoline methanol antimalarials with activity in vivo.[2] 
Certain biochemical and pharmacological evidence suggests that 4-aminoquinolines 
such as 5 interfere with heme processing[3] although this hypothesis has been challenged.[4] 
The poor solubility of these bisquinolines in common solvents necessitated use of theoretical 
methods in order to predict sites of protonation and lipophilicity. Despite the exact molecular 
sequence of events that lead to Plasmodial death not being known, it is currently accepted 
that processes leading up to and involving the formation of hemozoin (-hematin)iican be  
                                                          
iFour ferrous-protoporphyrin IX molecules, prosthetic adducts of hemoglobin, are enzymatically catabolized per 
molecule of hemoglobin by parasites. Fe(II)PPIX is oxidized to form Fe(III)PPIX and is denoted  hematin 
(-hematin), and possesses an axial OH substituent. Following biomineralisation, it is chemically identical to 
β-hematin (synthetic) known as hemozoin. In this biomineral, coordination of the central iron atom of one 
molecule to one carboxyl of the adjacent molecule forms a reciprocal dimer (rather than an infinite 
polymer).  Synthetic β-hematin obtained chemically in acidic conditions in vitro appears identical to physical 
and spectroscopic characteristics of native, parasite produced pigment. [5] aS. Pagola, P. W. Stephens, D. 
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disrupted in vitro by 4-aminoquinolines[6] and quinoline methanols.[3c] 
The absence of fluorine in mammalian systems as well as the high natural abundance 
of this NMR active isotope (19F)[7] has been previously exploited as a sensitive probe for 
quinoline receptor binding in solution.[8] Fluorine remains a popular choice for modifying 
leads inspired by natural products into useful drugs.[9]  
Cartographic analysis[10] based on mass spectroscopy of 1 distribution within 
Plasmodia has revealed its accumulation profile.[11] Interestingly, when first tested, Andersag 
et al [12] found that the trifluoromethyl bioisostere 4b of chloroquine 4a failed to confer 
advantages of incorporating fluorine in a molecule. Subsequently, this compound has been 
reconsidered as a useful compound for evaluating its antiparasitic activity in vivo; a result 
subsequently confirmed[13] against both sensitive and resistant strains in vitro. 
Van der Werf et al.[14] pioneered bioisosteric replacement of the hydroxyl group of 
amodiaquine 8a with fluorine, which resulted in less activity than 8a in vivo.[15] Although, 
this known compound also showed a corresponding loss of antimalarial potency when 
compared to amodiaquine in vitro, the need for new antimalarials was such that it was 
successfully patented much later.[16] A greater degree of success has been achieved in the 8-
aminoquinoline class of compounds, such as WR 238, 605 (Tafenoquine 9), which benefit 
from judicious introduction of trifluoromethyl substituents into the side chain.[17] From the 
latter half of the twentieth century, impact on metabolism by the host has become an 
important regulatory factor and fluorine now occurs in almost ~20 % of new drug 
introductions.[9]   
The synthesis and pharmacological profile of 1 resulted from the antimalarial program 
initiated by the US Army during World War II; the drug came into use after the end of the 
                                                                                                                                                                                    
S. Bohle, A. D. Kosar, S. K. Madsen, Nature 2000, 404, 307-310bM. A. Ambele, B. T. Sewell, F. R. 
Cummings, P. J. Smith, T. J. Egan, Crystal Growth & Design 2013, 13, 4442-4452. 
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US-Vietnam conflict.[18] A mefloquine progenitor, 2 was first disclosed in a comprehensive 
survey of antimalarials by Wiselogle,[18f] which also showed that in quinine 3 the 
quinuclidine ring could be simplified. They also showed that the methoxy group could be 
replaced by halogens (concurrently enhancing overall drug lipophilicity) resulting in 80 times 
greater activity than 3, initially in a duck (Plasmodium cathemerium)[18c] and subsequently in 
a murine model of malaria (Plasmodium berghei).[4b, 18g, 18h] Introduction of the lipophilic 
groups into position 2 of both 1 and 2 effectively delayed premature metabolic inactivation at 
this position by oxidation, an assumed weakness of 3.[19] Unfortunately, the prolonged 
photosensitizing action of 2 prevented further development of this seco-derivative into a 
clinically useful drug.[4b, 18h] By contrast, the introduction of trifluoromethyl (CF3) groups into 
positions 2 and 8 was dictated by bioassay-guided antimalarial screening. This provided a 
compound with an improved antimalarial/pharmacological profile against Plasmodium 
berghei in vivo.[18b, 18c] Similarly, the exact role of substituent positioning, especially chlorine 
on position 7 in 4-aminoquinoline antimalarials (Figure 1, 4a; 5) has never been adequately 
clarified. Presumably the chlorine groups in 5 impart improved lipophilic and/or 
pharmacokinetic properties, but they may also serve a yet undefined pharmacodynamic role. 
Studies of chloro and des-chloro analogs in a heme binding assay suggest that this group in 
the 7-position enhances binding of chloroquine-like drugs to the putative monomeric heme 
drug target[20] or interpenetrating a heme -oxo dimer.[21] The structural significance of 
halogenated substituents remains unknown but can certainly modulate metabolism in both 
parasite and host by “halogen blocking”  receptors.[22]  
10.1002/chem.201605099Chemistry - A European Journal
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Figure 1. Structural formulae of known and novel antimalarials described in this study, 
wherein 1a represents mefloquine (cycloaliphatic piperidinyl ring highlighted in magenta), 2 
(6, 8-Dichloro-2-phenyl-quinolin-4-yl)-piperidin-2-yl-methanol, 3 quinine, 4a chloroquine. 5, 
6, 7 without additional letters are used generically to describe any isomer. There are two 
isomers for these three compounds named as -trans (R-R) with trans geometry, and -cis (R,S) 
with cis geometry, with the identifiers equatorial (eq) and axial (ax), respectively, referring to 
the position of the substituent amino nitrogen atoms relative to the cyclohexane ring. 8a 
represents amodiaquine, 9 WR 238,605 (Tafenoquine) [17] and 10 metaquine.[23] 
 
One enantiomer of 4 demonstrated greater antimalarial efficacy than the other.[24] 
Similarly, enantiomers of 1a possess differing pharmacodynamic and pharmacokinetic 
profiles.[25] Potent compounds developed using a putative antimalarial receptor model include 
10.1002/chem.201605099Chemistry - A European Journal
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individual enantiomers of (±)-trans-N1,N2-bis-(7-chloroquinolin-4-yl)cyclohexane-1,2-
diamine (5-trans, ID50 < 2.5 mg/kg, 5.7 mmol/kg) as well as its structural isomer 5-cis see 
Figure 1).[2]  
In 1998, Ismail et al. reported a molecular mechanics study detailing the range of 
binding geometries of metaquine (10, Figure 1) to hematin.[26]  In this report, a number of 
close contacts with the receptor[22] were revealed, involving hydrogen bonds. Such 
observations, prompted the construction of a lead compound incorporating bulky CF3 
groups[7, 27] in positions 2 and 8 of the quinoline ring and bridged at position 4 with (±)-trans-
1,2-diaminocyclohexane to make a bis-(mefloquine/4-aminoquinoline) hybrid. In addition, 
one or more suitably positioned CF3 groups were expected to modulate, either favorably or 
unfavorably, lipophilicity[7, 28] as well as protect various antimalarials from xenobiotic 
metabolism.[7, 29]  
In order to further refine a generalized receptor model[23]  in this current investigation, 
we examined factors modulating antimalarial activity and explored possible homology with 
mefloquine-type compounds. A mefloquine/bisquinoline hybrid was constructed to ascertain 
what effect this would have on antimalarial activity in vivo and (i) to elucidate hydrogen 
bonding sites within these drugs and the influence of CF3 substituents; (ii) to explore the 
potential sites of protonation through quantum mechanical calculations[23] and (iii) to examine 
these interactions using X-ray crystallography and extensive DFT calculations involving 
interactions of various ligands with heme. 
 
Results and discussion 
Synthesis 
Compounds 5 and 6 were constructed using anhydrous NMP/triethylamine as reported 
previously.[2] The target substance (±)-trans- N1,N2-bis-(2,8-ditrifluoromethyl-quinolin-4-yl) 
10.1002/chem.201605099Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
  8 
cyclo-hexane-1, 2-diamine 7c was constructed by refluxing freshly distilled (±)-trans-1,2-
diaminocyclohexane with two equivalents of the corresponding 4-halo-2,8-bis-
trifluoromethyl substituted quinolines under a blanket of argon. Use of anhydrous N-
methylpyrollidinone (NMP)/ triethylamine under reflux encouraged dimer formation 7c [2] 
(Figure 2). 
 
Figure 2. Stepwise de-halogenoamination with SNAr reaction illustrating mono- and bis-
quinoline formation where (R2 = H or CF3; R7 = Cl or H, or various combinations thereof; R8 
= H or CF3). 
 
When 4-bromo (or 4-chloro)-2,8-trifluormethylquinoline was used for the SNAr 
(aromatic nucleophilic substitution) reaction, the reaction mixtures always became blue-black 
despite the presence of a protective atmosphere of argon. It is possible that the reactants or 
products were photosensitive, hence all further experiments were conducted in aluminum foil 
covered reactors. Both 4-chloro- and 4-bromo-2,-8-(bis-trifluoromethyl)-quinoline reacted 
with (±)-trans-1,2-diaminocyclohexane triethylamine/NMP (180 oC, 5 days, sand bath) to 
provide the required product 7c in 88 % crude yield.[2] Repeated recrystallization of the crude 
brown/black reaction mixture from acetone/HCl gave analytically pure 7a (44 % yield). The 
10.1002/chem.201605099Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
  9 
(±)-trans-N1-(2,8-di-trifluoromethylquinolin-4-yl) cyclohexane-1,2-diamine intermediate 12 
(Figure 2) was detected by spectrometry as an intermediate. The poor solubility profile, 
typical of such salts e.g. 5, [2] prevented the acquisition of NMR spectra of the salt 
necessitating conversion to the free base for such experiments. Nevertheless, the solubility of 
7c in DMSO was still inadequate, necessitating long spectral acquisition times and the use of 
a probe optimized for 13C HMBC and HSQC. A convenient, focused microwave preparation 
unlike the thermal synthesis, formed fewer dark by-products, is given in the Supporting 
Information. 
EI-MS spectra (m/z = 640 Da) revealed loss of a fluorine radical from the mass ion 
leading onto complex fragmentation and rearrangement phenomena (not shown). Since the 
base ion was m/z  = 36 (with the expected chlorine isotope patterns), this verified the 
(unexpected) presence of 7c as a hydrochloride salt. Additional evidence from both nominal 
and accurate positive ion high resolution electrospray ionization-mass spectrometry of the 
free base confirmed the identity of the compounds (see Supporting Information). 
 HPLC analysis showed monomeric impurities such as 11 were absent in the purified 
compounds used in the studies reported here. Positive-ion HR-ESI-MS was performed to 
confirm whether compounds 6-trans and 7c-trans were singly or doubly protonated 
(Supporting Information). Results indicated that both compounds were exclusively mono-
protonated. The resultant accurate mass positive ion spectra indicate good agreement between 
predicted and observed mass spectra (Table 1 and Supporting Information).  
Only the 4-aminoquinoline compounds 5 and 6 formed strong complexes with heme 
in electrospray experiments using methanol as the solvent (see Supporting Information). The 
interactions with heme of both 6-trans and 7c-trans as well as their protonated species, were 
studied further using molecular modeling methods (see below). 
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Spectroscopic Studies  
The state of ionization of antimalarial drugs is influenced by the environmental pH for 
example whether or not the drug is in the acidic digestive vacuole of Plasmodium. In order to 
determine the effect of protonation on 6-trans and 7c-trans the UV spectra were determined 
in DMSO and in trifluoroacetic acid (TFA). The compounds exhibited similar UV spectra 
with two-three maxima in DMSO and TFA (Table 2 and Figure S17) with chromic shifts 
reflecting conformational changes upon protonation which were subsequently investigated 
using quantum mechanics. Protonation of 6-trans in DMSO results in a reduction of basicity 
which caused a hyposchromic shift of a  to * band in TFA whereas the opposite was noted 
for 7c-trans (bathochromic shift). These observations are consistent with previous studies on 
related heterocyclic compounds, in which a hypsochromic shift has been related to  
protonation at the endocyclic nitrogen whereas bathochromic shift is associated with 
protonation at the exocyclic nitrogen.[30] Protonation of the endocyclic nitrogen changes the 
effective electronegativity of this position, the change in the charge on the nitrogen atom 
upon excitation determines the magnitude of the bathochromic spectral shift upon protonation 
(or deprotonation of the cation).[31] The increase in extinction coefficients of 7c-trans from moving 
to an increased hydrogen bonding environment reflects the geometrical change involved on the 
torsion angles upon protonation and its subsequent interaction on the chromophore. In the case of 6-
trans, the corresponding increase of the extinction coefficients from a slightly basic (DMSO) to an 
acidic medium reflects the change in geometry on protonation of the endocyclic nitrogen at position 1 
as well as hydrogen bonding of the endocyclic nitrogen that is known to add as a proton donor. In 
both 6-trans and 7c-trans the change from a basic to hydrogen bonding solvent increases the 
extinction coefficients as expected. These results are consistent with arguments advanced by 
Ganguly and Banerjee involving secondary amines.[32] The shifts in the UV spectra could 
therefore be used to establish both the state of protonation and determine intra-cellular 
trafficking in vitro.  
10.1002/chem.201605099Chemistry - A European Journal
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Table 1. Observed and predicted masses for 6-trans and 7c-trans. 
COMPOUND PREDICTED OBSERVED DISCREPANCY 
6-trans 505.1821 505.1805 3 ppm 
7c-trans 641.1575 641.1491 13 ppm 
 
Table 2. UV-spectroscopic data for 6-trans and 7c-trans indicating chromic shifts upon 
ionization. 
Compound Solvent Bands 
6-trans DMSO 337 nm ( ~ 24,138) 
 
 351 nm ( ~ 26,601) 
6-trans TFA 328 nm ( ~ 40,367) 
342 nm ( ~ 46,789) 
7c-trans DMSO 354 nm ( ~ 21,675)i 
7c-trans TFA 338 nm ( ~ 37,615) 
344 nm ( ~ 40,367) 
362 nm ( ~ 55,963) 
iBroad band. 
 
NMR experiments 
The projected receptor binding experiments require unequivocal identification of both 
quaternary centers associated with the trifluoromethyl group, because they could be sensitive 
probes for the drug-binding environment. Hence, both trifluoromethyl groups were identified 
by the magnitude of the 1J C-F and 2JC-F coupling constants. Partial analysis of vicinal coupling 
constants ascribed to the (±)-trans-1,2-diamino-cyclohexane bridging unit suggests that the 
10.1002/chem.201605099Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
  12 
axial-axial conformer predominates in DMSO-d6 solution, at room temperature, an 
observation consistent with the solid state structure (see Figure 7). The latter reveals the 
desired position of hydrogen bonding, the NH proton being split into a doublet by one of two 
of the eight protons found in this complex, a result confirmed by COSY experiments (Figure 
3). This condition remained unchanged in the presence of both strongly and weakly 
coordinating solvents such as NMP and methanol. The result confirms that the exocyclic 
secondary amino group participates in hydrogen bonding interactions confirming its role as a 
donor group and probably acts with heme in a similar fashion (See modeling section).[2, 23] 
 
Figure 3. COSY spectrum of 7c-trans. Marked is the cross peak between NH at A and a 
molecule of water at B. 
 
Pharmacology 
Compound 7c injected subcutaneously (s.c.) twice daily in mice infected with 
chloroquine-sensitive P. berghei[2] (dose levels 10 and 50 mg/kg, 23.6 and 117.8 mmol/kg 
respectively; n = 5) had no effect on parasitaemia 72 hours after inoculation with 
Plasmodium, when compared with vehicle-treated animals (control 64.8 ± s.e.m. 2.1 %, 7c 10 
10.1002/chem.201605099Chemistry - A European Journal
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mg/kg (23.6 mmol/kg) 61.6 ± 1.55 %, 7c 50 mg/kg (117.8 µmol/kg) 66.1 ± 2.7 % 
erythrocytes contained Leishman-positive bodies, P > 0.05, Mann-Whitney U). Repeated 
administration of 7c in these doses over the three day period was also without effect on body 
weight gain, colonic temperature, locomotor activity or, by visual inspection, the general 
autonomic state of mice when compared with control animals receiving vehicle (olive 
oil/DMSO 24:1, injection volume 10 ml/kg s.c.). In contrast, 6 tested in this murine model of 
malaria was antimalarial (ID50 5.9 mg/kg; 14.9 µmol/kg). Previously, we have tested 6 [2a] 
and found it to have less antimalarial activity than the two configurations of 5,[2a] suggesting 
its interaction with the target receptor is sterically unfavorable. A similar loss of antimalarial 
potency in the trifluromethyl analog of chloroquine may explain why it was not developed 
further.[33] Compound 6 injected s.c. in mice infected with P. berghei (dose range 6.3-252.2 
µmol/kg, 5 doses in 72 hours) produced no observable adverse effects. Chloroquine 
diphosphate in this model had an ID50 of 4.3 mg/kg (8.3 µmol/kg). 
Comparison of the data for putative 4-aminoquinoline antimalarials containing CF3 
groups in both the 2- and 8- positions, indicates that they all showed decreased antimalarial 
activity compared to their 7- CF3 counterparts either in vitro or in vivo.
 [13-16, 34] 
 
Theoretical Investigations: Comparison of quinoline methanol behavior versus 4-
aminoquinolines. 
Conformational analyses were carried out on mefloquine 1 and its progenitor 2. A 
comparison of the crystal structures of different forms of mefloquine, namely () mefloquine 
methylsulfonate monohydrate, () mefloquine hydrochloride methanol solvate,[35] () 
mefloquine free base, and (-) mefloquine hydrochloride hydrate,[36]  shows that all four 
structures contain short N...O contacts of 2.73-2.94 Å, with a geometry similar to that shown 
in Figure 4, which can be considered as hydrogen bond interactions.  
10.1002/chem.201605099Chemistry - A European Journal
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Conformational analysis on 1a using molecular dynamics was undertaken. The 
simulations were carried out at 3000 K with step sizes of 1 fs. 1000 structures were saved at 1 
ps intervals and geometry optimized by molecular mechanics using the Dreiding force field 
within Cerius2. [37] Two low energy conformations were obtained in this study, which differed 
only in the O-C-C-N torsion angle. These were subsequently geometry optimized using the 
Gaussian09 program[38] with DFT at the B3LYP/6-31+G*  level of theory: the structure 
which contained a torsion angle of -68.2o with a hydrogen bond had a lower energy by 4.5 
kcal mol-1 than the alternative structure with a torsion angle of 76.2o without a hydrogen 
bond. This result confirms that the lowest energy conformation of 1a, shown in Figure 4, 
contains an intramolecular hydrogen bond,[39] a result consistent with the experimental crystal 
structures.[35-36, 40] These calculations were repeated using the PCM[41]  continuum solvent 
method with a dielectric constant of 78.8, appropriate to water, and the difference in energy 
for the two conformations decreased to 2.6 kcal mol-1 which is smaller than the 4.5 kcal mol-1 
difference calculated in the gas phase but still significant. 
10.1002/chem.201605099Chemistry - A European Journal
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Figure 4. The lowest energy conformation of 1a. Carbon black, nitrogen blue, oxygen red, 
fluorine green.  The intramolecular hydrogen bond is shown as a dotted line. 
 
The protonation preferences of 1a were investigated because they may assist in 
defining electrostatic interactions with the putative heme receptor. The crystal structures of 
the protonated 1a all show that the exocyclic nitrogen is protonated in preference to the 
aromatic nitrogen.  This result was consistent with observed crystal structures for both 
quinine and quinidine salts. The energies of the protonated mefloquine ions showed a 
difference of 6.6 kcal mol-1 in favour of protonation at the exocyclic piperidine nitrogen. This 
result was consistent with crystallographic observations.[35-36] 
10.1002/chem.201605099Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
  16 
This preference of side chain protonation was also consistent with the fact that similar 
molecules, such as quinine and quinidine, were also initially protonated on the aliphatic 
nitrogen rather than the aromatic nitrogen atom. The pKa values of quinine have been 
measured as 8.6 for the aliphatic and 3.5 for the quinoline nitrogen atoms,[42] respectively.  
Establishing the effect of the substituent CF3 groups that gave rise to this result was 
important.  Accordingly, model compounds 1b (mefloquine with the CF3 group in position 2 
removed and replaced by hydrogen), 1c (mefloquine with the CF3 group in position 8 
replaced by hydrogen) and 1d (mefloquine with both CF3 groups replaced by hydrogen) were 
created. The structures of these compounds were optimized with protonation at either type of 
nitrogen. The resulting energies, given in Table 3, showed that the presence of the CF3 group 
in position 2 significantly decreased the likelihood of the adjacent aromatic nitrogen being 
protonated in preference to the aliphatic nitrogen atom, whereas the presence of the CF3 in 
position 8 had a much smaller effect.  
 
Table 3. The energies in the gas phase calculated with DFT methodology with either the 
aliphatic (endocyclic piperidinyl) or aromatic nitrogen (endocyclic) atoms protonated. Also, 
included were values from models created from mefloquine by omitting specific CF3 groups.  
 
 Energies/kcalmol-1 
aliphatic N protonated – aromatic N protonated 
mefloquine 1a -6.6 
0.7 
-5.8 
2.1 
1b 
1c 
1d 
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The two CF3 groups allow, in principle, the formation of an internal bifurcated 
hydrogen bond to the adjacent protonated aromatic nitrogen. If such an interaction was 
possible, this could occur either from the CF3 group in the 2 or 8 position. From the CF3 
group in the 2-position, the fluorine would be in the plane of the quinoline-ring and the F...H 
distance would be 2.14 Å with an N-H...F angle of 104.6o. From the CF3 group in the 8-
position, a fluorine substituent in the plane of the aromatic ring would be 1.60 Å from this 
hydrogen with an N-H…F angle of 129.6o. 
There were, however, no examples in the Cambridge Crystallographic database[43] of 
either hydrogen bond formation, an observation that suggested that it is not likely to occur. 
However, what is clear is that the introduction of CF3 groups in either position 2- or 8- of the 
quinoline ring causes steric crowding around the aromatic nitrogen (whether protonated or 
not) that will modulate efficient interaction of this atom with the  heme receptor.[23]  
Calculations for 2 were repeated after geometry optimization showed an inter-ring 
angle of 9.9o between the phenyl ring in position 2 and the aromatic system. The energy for 
the conformation with a torsion angle for O-C-C-N of -67.5o containing a hydrogen bond was 
lower by 3.9 kcal mol-1 than that of the alternative structure with a torsion angle of 75.4o.  
When the calculations were repeated in a water environment, this second structure became 
the more favourable but only by 0.5 kcal mol-1. The lowest energy conformation is shown in 
Figure 5. 
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Figure 5. The lowest energy conformation of 2. Carbon black, nitrogen blue, oxygen red, 
chlorine green.  The intramolecular hydrogen bond is shown as a dotted line.  
 
The energies of the protonated compounds were next calculated for the conformations 
with a hydrogen bond. These showed a preference for the aromatic nitrogen by 4.2 kcal mol-1 
rather than the aliphatic nitrogen, thus the reverse situation to 1a. The phenyl ring substituent 
in the 2-position clearly has the opposite effect to that of the CF3 groups in 1a. 
 
A similar calculation was carried out for chloroquine 4a, using the crystal structure of 
the diprotonated diphosphate monohydrate[44] as the starting model. There were three possible 
nitrogens to be protonated: the aromatic nitrogen, the exocyclic 4-amino nitrogen and the 
10.1002/chem.201605099Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
  19 
diethyl aliphatic side chain nitrogen. The relative energies were calculated as 0, 34.1, 13.0 
kcal mol-1 respectively, a result consistent with the crystallographic results but not with 
experimental data[45] that show that the monocation resides almost exclusively in the alkyl 
amino protonated form (pKa1 = 7.94 +/- 0.02; pKa2 = 10.03 +/- 0.02) whereby ionization of 4a 
is controlled mainly by the change in enthalpy due to the significantly higher values of Ho 
compared with the entropic component, TSo.[45] 
 Subsequently, the structure of 5, Ro 47-7737 was investigated. There are two chiral 
carbon atoms, the two carbon atoms in the cyclohexane ring that are bonded to nitrogen. 
These give rise to two different isomers trans (R,R) and trans (S,S) (Figure 6). The structural 
cis-isomer was also investigated.  
The possible conformations of 5-trans (R,R) and 5-cis (R,S) structures were 
investigated with molecular dynamics and subsequent molecular mechanics energy 
minimization, which was followed by geometry minimization on the lowest energy 
conformations with the Gaussian09 program.[38] Utilizing molecular mechanics calculations, 
two low energy conformations were established for the (R,R) conformation with the two 
nitrogen atoms in equatorial positions (eq,eq) relative to the cyclohexane ring in the chair 
conformation but on DFT minimization, these two converged to an equivalent geometry. In 
addition, a third configuration named 5C with the two nitrogen atoms in axial positions 
(ax,ax) was established.  
The eq,eq conformation 5-trans has the lowest energy with the ax,eq and ax,ax 
conformations having higher relative energies by 5.1, 7.0 kcal mol-1, respectively. These 
relative energies increased significantly in water to 7.7, 8.6 kcal mol-1. These results can be 
compared with an energy difference found by Karle et al[36]  at the HF/6-311G level of 11.3 
kcal mol-1in favor of the (eq,eq) configuration over the (ax,ax) configuration for the 
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diprotonated compound.[2a, 36] The conformations can be characterized by the central torsion 
angles involving atoms C41-C32-N31-C1-C6-N11-C12-C21 (Figure 7). 
These angles were respectively -1.1, 158.2, -53.3, 158.7, -1.2o: -11.1, 111.7, -55.2, -
101.0, 135.5o;  and -127.9, 87.1, -165.6, 79.4, 0.0o for the 5-trans (eq,eq), 5-cis (ax,eq), and 
5C (ax,ax) conformations respectively. The first conformation 5-trans (eq,eq) was similar to 
that observed in the crystal structure of 7a (see later, Figure 7). A slightly different eq,eq 
conformation was observed in the crystal structure of the diprotonated dimethylsulfonate salt 
[40]
 where the torsion angles were 8.9, 103.3, -62.0, 104.2 -11.0o. Although this conformation 
was established as distinct in molecular mechanics calculations, as stated above, it converged 
to the aforementioned eq,eq structure on energy minimization with DFT.  
 
  
(a)                                                          (b)                                             (c) 
Figure 6. Lowest energy conformers of (a) 5-trans (R-R) (eq-eq), (b) 5-cis (R-S) (ax,eq) and 
5C (R-R) (ax,ax).  
 
In order to investigate the protonation pattern of the ligand, the eq,eq conformation of 
5-trans was chosen because it had a) the lowest energy and b)  the crystal structure of the 
related 7c-trans has been determined. This ligand (5-trans) was first protonated via one of the 
aromatic nitrogen atoms and then on a 4-amino exocyclic nitrogen atom to give relative 
energies of 0.0, 32.0 kcal mol-1, respectively, a result which is consistent with the observation 
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in chloroquine 4a that the 4-amino nitrogen atom is an unlikely site for protonation.  Similar 
differences in energies were obtained with the other two configurations 5-cis and 5C. 
Then two equivalent nitrogen atoms were protonated, the resulting energies in the 
(eq,eq) configuration in the gas phase were lower by 107.7 kcal mol-1 for two aromatic 
compared to two 4-amino exocyclic nitrogen atoms, a value that was more than twice that for 
the monoprotonated compounds, presumably because of the close proximity of the protonated 
4-amino exocyclic nitrogen atoms to each other. This observation was in agreement with the 
crystal structure of the (R,R) configuration, where the hydrogen atoms were located on the 
two aromatic nitrogen atoms in the diprotonated compound[40] and, indeed, form donor 
hydrogen bonds to the anions. These observations are consistent with a published biophore in 
which the endocyclic nitrogens act as proton acceptors while the secondary 4-aminoquinoline 
groups act as donors.[2, 23] 
Structures of 6-trans and 7c-trans were also studied by constructing starting models 
from the lowest energy (eq,eq) conformation of the trans 5-trans (R,R) configuration 
obtained previously. CF3 groups were subsequently added into position 7 for 6-trans and both 
2 and 8 for 7c-trans and results are compared to those for 5-trans in Table 5.  
 
Table 5. Comparison of energies (kcal mol-1) for structures 5-trans, 6-trans, 7a-trans and 7c-
trans. 
 
ΔE1 i   ΔE2 ii 
5-trans 256.0 32.0 
6-trans 263.1 31.8 
7a-trans 253.0 33.8 
7c-trans 244.3 34.7 
i
 ΔE1 = E(compound) – E(compound)H+, protonated at the aromatic nitrogen. 
ii
 ΔE2 = relative energy of compound protonated at the exocyclic nitrogen compared to the aromatic nitrogen. 
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The results shown in Table 5 allowed several conclusions to be drawn. First, the 
protonation preferences for the bisquinolines 5-trans, 6-trans, 7a-trans and 7c-trans were the 
opposite of those observed in 1a with the bisquinolines favoring aromatic protonation and 
with mefloquine 1a, aliphatic protonation in the gas phase, although it should be noted that 
the differences in energy for the bisquinolines were much larger than that for 1a. Indeed, 
protonation at the exocyclic nitrogen was very unfavorable for all four structures, the energy 
differences for all three molecules being over 31.7 kcal mol-1. Comparison of the protonation 
energies showed that the replacement of Cl with CF3 in the 7 position or the inclusion of CF3 
groups in the 2 and 8 positions induced only a small effect upon the preferences. The crystal 
structure of 7c-trans (R-R) was determined by X-ray crystallography and is illustrated in 
Figure 7.  
 
Figure 7. The structure of 7c-trans as determined by X-ray crystallography with ellipsoids at 
50 % probability. The solvent methanol molecule is not shown.   
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Figure 8.  The structure of 7c-trans showing the formation of a centrosymmetric dimer 
facilitated by N31-H…F172 hydrogen bonds labelled as a. The N(11)-H atom formed a 
hydrogen bond, labelled as b,  to the oxygen atom O(100) of a methanol solvent molecule.   
Hydrogen bonds a and b are shown as dotted lines. 
  
The five torsion angles in the C41-C32-N31-C1-C6-N11-C12-C21 link were 1.7, 
164.0, -52.2, 154.6, -5.5o  so the conformation was very similar to that obtained from the 
conformational analysis of 5-trans described above where the angles obtained were -1.1, 
158.2, -53.3, 158.7, -1.2o. The minimal difference indicates that the crystal packing, which 
involves the formation of a centrosymmetric dimer in which the two molecules are connected 
by hydrogen bonding between  N31 and  F172 (symmetry operation 1-x,1-y,-z) at 3.30 Å 
with H…F 2.53 Å and N-H…F 149o as shown in Figure 8, has little effect on the 
conformation. From Figure 8, it is apparent that the two aromatic rings at the centre of the 
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dimer are perforce parallel but the distance between them is ca 4.0 Å which is too long to 
indicate a significant π…π interaction. The angle between the two 10-membered aromatic 
moieties in the two halves of the molecule is 64.7o, thus the molecule is far from planar 
which has significant implications for its interaction with heme as discussed later. In addition, 
N11 forms a hydrogen bond to a methanol solvent molecule (N11-H…O100 N…O 2.93, 
H…O 2.22Å, N-H…O angle 141o), as also seen in the COSY spectrum (Figure 3). Notably, 
the solvent methanol forms close contacts to F374, F404, F372 (symmetry operation -x,-y,-z-
1) with O…F distances at 2.97, 3.15, 3.33 Å shown in Figure S34.  The significance of the 
formation of all these hydrogen bonds is clearly a crucial factor in the chemistry of 7c-trans 
and is further explored when considering the interactions of molecules, 5-trans, 6-trans, 7c-
trans with heme (see later). 
 
Binding of ligands to heme 
Antimalarial drug design was historically hampered by assuming a drug target whose 
identify shifted according to the popularity of known research from heme to DNA to proteins 
and other targets.[46] Consequently, initial work by Ismail[2a, 22] employed an extra-
thermodynamic approach to 4-aminoquinoline and 4-aminobisquinoline drug design, in 
which details of molecular interactions were not required.[47] Initially, speculation that a 
protein receptor could also be a drug target[48] then led to determination of putative maximum 
volumes of the receptor site (assuming it could be a macromolecule). This type of approach is 
now re-gaining favour and recognition of some of the limitations of target-based drug 
discovery,[49] has  prompted a "renaissance of a more holistic approach in which complex 
biological systems are investigated for phenotypic changes upon exposure to small 
molecules." [50]  Currently, in line with most investigators, the currently favoured 4-
aminoquinoline drug target is heme, released during the catabolism of hemoglobin. Although, 
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various proteins are now known to be also involved in processing heme within the parasite, 
including recently identified heme detoxification proteins[2a, 4a, 51] and kinases,[49a] it is 
currently unknown if 4-aminobisquinolines target such processes. Consequently, 
investigations interrogating the nature of various bonding interactions were considered using 
computational approaches and were limited only to heme. 
Dascombe et al.,[23] postulated that metaquine (10, Figure 1) could be complexed to 
hematin in several modes, especially via several non-bonded contacts including two 
intramolecular hydrogen bonds, one from an exocyclic N-H in 10 to the axial hydroxyl group 
in hematin and the second from the associated endocyclic quinoline nitrogen atom to the 
carboxyl group in hematin. This was dubbed an “above face” interaction (i.e. that containing 
the axial hydroxyl group) as opposed to binding on the obverse (below) face, which favors π-
π interactions with suitable drugs. A previous modeling study[52] on chloroquine 4a 
concentrated on this obverse binding and found significant π-π interactions but above face 
interactions were not considered. It will be noted that compounds 5, 6 and 7c (Figure 1) all 
contain a cyclohexane bridge between two aromatic moieties, which creates a very different 
shape and therefore  interactions with the receptor were likely to be different from those 
involving 10 and for that matter 4a.[23] One major change was that in the trans  isomers of 5-
trans, 6-trans, 7c-trans, it might be  possible for  both exocyclic N-H groups to hydrogen 
bond to the hydroxyl group. In addition, the existence of the CF3 groups in 6 and 7 permit 
alternative hydrogen bonding from the carboxylic acid group to a fluorine rather than to the 
endocyclic nitrogen atom. Indeed it could also be possible for the chlorine in 5 to be involved 
in such an interaction.  
These possibilities were first investigated by molecular mechanics using the Cerius2 
software51 with the Universal Force Field and the most likely resulting structures were 
optimized. Calculations on these structures were then carried out using density functional 
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theory methods as implemented in Gaussian-09,[38] following methods and procedures as 
reported and tested previously.[53] In general, the unrestricted B3LYP hybrid density 
functional theory was used for all geometry optimizations and frequencies.[54] All structures 
were optimized with an LANL2DZ basis set on iron (with core potential) and 6-31G* on the 
rest of the atoms (H, C, N, O): basis set BS1.[55] It was assumed in all calculations that iron 
was Fe(III) with five unpaired electrons so molecules were neutral when a hydroxide was 
present and +1 otherwise. 
 In the starting models, the ligands were given their lowest energy conformations and 
hematin its crystal structure.[56] Models of 5-trans, 6-trans and 7c-trans were complexed with 
heme in several different ways based on our current knowledge of the system. The crystal 
structure of both heme[56a] and a limited number of antimalarials of the quinoline methanol 
class covalently bound to heme have been obtained but the 4-aminoquinoline class has 
proved elusive[56b] and investigators have resorted to EXFAS studies and modelling 
studies.[21] Consequently, it has been shown that the mode of action of quinoline methanols is 
at heme but unlike 4-aminoquinolines, they displace the axial group to form a Fe-O bond 
which is also found in all other compounds of this class (e.g. halofantrine,[57] Cinchona 
alkaloids especially 3[58] and 1a).[59] This type of covalent adduct can enforce a - 
interaction between ligand and receptor to minimize intramolecular interactions. 
 In terms of frequency, the most popular literature depiction is a - type interaction 
between ligand and heme receptor,[60] followed by some studies invoking a metal-N bond.[61] 
In contrast, models invoking electrostatic interactions (hydrogen bonding) have 
occasionally[62] been investigated and indeed such an arrangement has subsequently been 
found in a crystal structure of a gallium hemozoin analogue-chloroquine complex  (but not 
with the monomeric heme considered in the current study).[63]  Studies have also considered 
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interactions with a heme -oxo dimer using EXAFS[21, 64] but these were beyond the scope of 
the current investigation. 
Following these precedents, several modes of interaction of molecules 5-trans, 6-
trans, 7c-trans with heme were considered. These included structures of various types: (a) in 
which the ligand displaced the hydroxide and an Fe-N bond was formed (complexes 1 and 2, 
Figure 9); (b)  in which  the ligand was positioned to the edge of the heme forming hydrogen 
bonds to the carboxylic acid groups of the heme (complexes 3 and 4, Figure 10); (c) 
structures with the ligand on the obverse face (complexes 5-8, Figure 11 and 12);  (d) 
structures with the ligand forming above face contacts (complexes 9-12, Figure 13) and ( e) 
structures were created in which two ligands were involved on either side of the heme 
(complexes 13, 14, Figure 14). Finally, a calculation was carried out for a heme-mefloquine 
complex (complex 15, Figure 15).  
The structures minimized by molecular mechanics were then reinvestigated by DFT 
calculations as previously described. The energies of interaction were calculated as 
E(complex) – E(Heme) – E(ligand) with E(OH) also included when present.  
The structures obtained all converged satisfactorily and are illustrated in Figures 9-15.  
Details of the calculations and coordinates are included in the Supporting Information. 
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Figure 9. DFT optimized structures of complexes 1 and 2, with distances in Å. Hydrogen 
bonds shown as dotted lines. 
 
Structures of complexes 1 and 2 containing ligands 5-trans and 6-trans, respectively, 
are shown in Figure 9 and are particularly interesting as the input models included a Fe-
N(quinoline) bond but no additional hydrogen bond. However, on geometry optimization of 
complex 1, two  hydrogen bonds were formed, one between an OH from a porphyrin 
propionic acid group and a quinoline nitrogen atom with O-H…N 1.72 Å and the other 
between carboxylic acid groups with O-H…O  1.78 Å respectively both distances indicating 
strong hydrogen bonds. The energy of interaction was calculated as -36.7 kcal mol-1.  
 The structure of complex 2 also contained donor hydrogen bonds from the carboxylic 
OH groups but in this case the O-H that formed a hydrogen bond to the second carboxylic 
OH group with O-H…O 1.90 Å also formed a weak hydrogen bond to a fluorine atom O-
H…F 2.45 Å. This second carboxylic OH group formed a strong hydrogen bond to a second 
fluorine atom O-H…F 1.93 Å, thus very different to that observed in complex 1, in which 
this oxygen forms a hydrogen bond to nitrogen The difference between the two structures 
confirms our hypothesis expressed above that the CF3 groups in 6 and 7 could readily be used 
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to stabilize the complex. The energy of interaction was similar to that in found for complex 1 
at -35.5 kcal mol-1. 
The structures of complexes 3 and 4 containing ligands 5-trans and 6-trans 
respectively with edge type interactions followed similar patterns to orientations established 
in our previous work[23, 62] for other ligands in that the ligands were positioned forming 
hydrogen bonds to the two carboxylic –OH groups. The structures were very similar in which 
the two quinoline nitrogen atoms act as acceptors with O-H…N distances of 1.72 and 1.80 Å 
in complex 3 and 1.73, 1.81 Å in complex 4. The energies of interaction at -16.7, -24.4 kcal 
mol-1 respectively were significantly less than that observed for complexes 1 and 2. This is 
opposite to the relative interaction energies found where the energy of the edge type 
interactions was favoured in both chloroquine 4a and metaquine 10 (data not shown)[65] over 
the covalent bond structure presumably because of the interactions imposed by the folded 
nature of ligands 5-trans and 6-trans. 
 
 
Figure 10. DFT optimized structures of complexes 3 and 4 showing edge-type interactions 
with distances in Å. Hydrogen bonds shown as dotted lines 
 
The structures of complexes 5 and 6, shown in Figure 11 with ligands 6-trans and 7c-
trans, respectively, are particularly interesting in that they converged to structures very 
different from the input structures which contained π…π stacking between the heme and the 
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ligand on the obverse face in a planar conformation. The conformation of the ligand totally 
changed to a folded geometry closer to the energy minimum discussed above.  
In the structure of complex 5, four close interactions were observed, the shortest being 
one between a methyl hydrogen from the heme to a fluorine H…F 2.44 Å. There were also 
two interactions between C-H groups from the ligand and two of the nitrogen atoms in the 
heme (H…N 2.73, 2.89 Å). There was also an O-H…N interaction with H…N 1.875 Å 
.However the energy of interaction for this structure was only -8.8 kcal mol-1. 
In the structure of complex 6, there is a hydrogen bond between the carboxylic acid 
oxygens O-H…O 1.95 Å while the other significant interactions are between a methyl 
hydrogen on the heme which forms close contacts to two fluorine atoms from different CF3 
groups at 2.79, 2.64 Å. In addition a hydrogen atom from a =CH2 group forms a contact of 
2.55 Å with a fluorine atom. Thus, both CF3 groups in 7c-trans form contacts with the heme, 
but the resulting energy of interaction is a small -4.9 kcalmol-1.   
 
Figure 11.  DFT optimized structures of complexes 5 and 6 with distances in Å. Hydrogen 
bonds shown as dotted lines  
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The structure of complex 7, shown in Figure 12 was created in an attempt to ascertain 
whether one or both carboxylic acids could enter into the cavity between the two aromatic 
sections of 7c-trans. The input model contained both carboxylic acids in the cavity, but the 
final optimized structure contained only one which formed a donor hydrogen bond to a 
fluorine atom (O-H…F 1.98 Å). In addition there was a hydrogen bond between carboxylate 
oxygens atoms with (O-H…O) 1.90 Å. The energy of interaction is -11.7 kcal mol-1.   
The structure of complex 8, shown in Figure 12, involved an attempt to stack the two 
molecules involving π…π interactions. The ligand was placed on the opposite side to the 
hydroxide on heme (e.g. the obverse face). In the resulting structure the main interactions are 
between a carboxylic acid and the ligand, via O-H…F interaction of 2.01 Å and a C-H…O 
interaction from the ligand to the second oxygen of 2.36 Å. In addition there are weak 
interactions from a methyl hydrogen to F at 2.54 Å and an aromatic C-H to N(heme) at 2.58 
Å as shown in Figure 12. The energy of interaction is -9.6 kcal mol-1  
 
 
 
Figure 12.  DFT optimized structures of complex 7 and 8 with distances in Å. Hydrogen 
bonds shown as dotted lines 
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                               Complex 9                                             Complex 10 
 
 
 
                                      Complex 11                                         Complex 12 
Figure 13.  DFT optimized structures of complexes 9, 10, 11 and 12 with distances in Å. 
Hydrogen bonds shown as dotted lines 
 
The structure of complex 9 which contains 6-trans, shown in Figure 13 was an 
attempt to ascertain if a stable structure could be obtained in which the two exocylic N-H 
bonds could both form hydrogen bonds to the heme hydroxide. In the event, the two N-H…O 
distances optimized to 2.08, 2.78 Å so there are significant interactions but with one much 
shorter than the other. Presumably the presence of the hydrogen on the oxygen atom in the 
hydroxide precludes both N-H groups from forming similar short interactions. This structure 
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also contains an intramolecular hydrogen bond between carboxylic acid groups with O-H…O 
1.92 Å. The energy of interaction was quite favorable at -20.0 kcal mol-1  
Three further complexes 10, 11 and 12 involving 5-trans, 6-trans and 7c-trans 
respectively were also built to investigate the interaction of the two exocyclic N-H bonds 
with the heme hydroxide. In these cases the starting model including two hydrogen bonds 
from N-H to O but in the optimized structures, shown in Figure 13, only one such interaction 
was maintained with the other H…O distance increasing to > 4.0 Å. However, in addition to 
one N-H…O hydrogen bond at distances 1.97, 1.94, 1.90 Å, the optimized structures showed 
different additional hydrogen bonds involving a carboxylic OH group. In complex 10, 
containing 5-trans, there is an O-H…N hydrogen bond at 1.78 Å, in complex 11 containing 
6-trans, a O-H…F hydrogen bond at 1.99 Å while in complex 12 containing 7c-trans the O-
H forms a bifurcated hydrogen bond to F at 2.08 Å and N at 2.21 Å. Despite these differences 
the energies of interaction for the three complexes were very similar at  -19.0, -18.3, -19.0 
kcal mol-1, respectively. 
 
Figure 14  DFT optimized structures of complexes 13 and 14 with distances in Å. Hydrogen 
bonds shown as dotted lines 
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The structures of complexes 13 and 14 which involve two ligands (6-trans, 7c-trans 
respectively) sandwiching one molecule of heme are shown in Figure 14. As might be 
expected, the two structures show both obverse and above face interactions, which have been 
observed previously in the models with just one ligand. For example complex 13 exhibits 
three acceptor hydrogen bonds on the obverse face, namely an N…OH interaction with heme 
of 1.81 Å and two F…H-C interactions of 2.52 and 2.48 Å. On the above face, the ligand is 
involved in two donor hydrogen bonds, two to the heme hydroxide N-H…O of 1.99 Å and a 
C-H…O of 2.36 Å and an acceptor hydrogen bond from a carboxylic acid oxygen N…H-O at 
1.79 Å. 
A different pattern of bonding is observed from complex 14 where there is only one 
significant obverse face interaction of O-H…F 1.98 Å, but several above face including 
strong N-H…O 1.84, O-H…F 1.99 Å and weak hydrogen bonds C-H…F of 2.53 and 2.67 Å. 
It is thus apparent that in both structures the interactions are stronger on the above face side. 
It is also noteworthy that in both structures, the two carboxylic acids are hydrogen bonded to 
the ligands on opposite sides. The interaction energies are -42.2, -21.3 kcalmol-1 respectively 
showing that the interactions are far stronger in 13 than in 14.  
The final structure in this section shows a possible structure for protonated 
mefloquine forming complex 15 with heme, shown in Figure 15. 
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Figure 15. DFT optimized structures of complex 15 showing edge-type interactions with 
distances in Å. Hydrogen bonds shown as dotted lines. 
 
In this structure the mefloquine was protonated at the aliphatic (piperidyl) rather than 
the aromatic nitrogen, consistent with the calculations above and crystallographic 
observations. This hydrogen atom formed a very strong hydrogen bond to the heme 
hydroxide with N-H…O 1.58 Å. Other hydrogen bonds involved two carboxylic oxygen 
atoms O-H…O 2.07 and an O-H…F between the ligand and heme of 2.45 Å. The energy of 
interaction was -40.2 kcalmol-1. Therefore, it could be considered to pre-organize this 
fluorinated quinolone methanol to attack heme by forming an axial Fe-O(alkoxide) bond as 
seen in crystal structures.[59] But, an equivalent 4-amino-quinoline crystal structure, such as 
for chloroquine 4a, has yet to be found.[61]  
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Table 6. Interactions energies (kcal mol-1) for complexes 1-15 in the gas phase and in water. 
 
Complex E(gas)        E(water) 
1 -36.7 -24.3 
2 -35.5 -23.4 
3 -16.7 -14.0 
4 -24.4 -20.7 
5 -8.8 -6.9 
6 -4.9 -4.3 
7 -11.7 -5.0 
8 -9.6 23.0 
9 -20.0 -10.0 
10 -19.0 -10.4 
11 -18.3 -11.2 
12 -19.0 -8.7 
13 -42.2 -33.9 
14 -21.3 -9.6 
15 -40.2 -15.4 
 
 
Of course the interaction of ligands with heme does not occur in the gas phase and 
therefore the calculations were repeated in the solvent water PCM method in Gaussian09.[38] 
The same starting models were used as in the gas phase calculations, but notably the 
structures refined to similar structures. The energies of interaction are compared to those 
from the gas phase in Table 6.  While the order of E values remains the same, with 
complexes 1 and 2 which contain a Fe-N bond having the prefered values of -24.3, -23.4 kcal 
mol-1, complexes 3 and 4 with edge-type interactions now give closer  E values at -14.0, -
20.7 kcal mol-1. 
 Several conclusions can be drawn from these DFT calculations. One general 
conclusion is the overriding importance of hydrogen bonds in the structures of these 
complexes. It is clear that in all structures, the relative positions of the heme and ligand are 
governed by the formation of hydrogen bonds. In all cases the carboxylic acid groups of the 
heme form hydrogen bonds, sometimes between each other but also with the exocyclic 
nitrogen, the quinoline nitrogen and/or the fluorine atoms of the CF3  groups in 6-trans and 
7c-trans although no hydrogen bonds were found with the chlorine atoms in 5-trans.  While 
not in itself viable having a relative small interaction energy, the structure of complex 6 is 
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particularly interesting as the ligand is linked to the heme via C-H…F rather than O-H…F 
hydrogen bonds.  Taking the energies into account it can be concluded that the most likely 
structures are those which contain a covalent Fe-N bond (complexes 1,2) or the edge type 
interactions, (complexes 3,4), which are the most stable whether there is an hydroxide bonded 
to the iron or not. However, in the presence of the hydroxide, structures in which the ligand 
N-H moieties form hydrogen bonds to the hydroxide are also possible, although it would 
appear from the structure of complex 8 that one strong hydrogen bond could be formed. In all 
our studies we were unable to find a satisfactory low energy structure containing π…π 
stacking. Indeed it was found that any input structure containing stacking reverted on 
optimization to one containing hydrogen bonds involving one of the carboxylic acid groups 
of heme.  The calculations on the sandwich complexes, 13 and 14 show that it is possible and 
indeed energetically favourable for two ligands to be attached to one heme but it is clear that 
the interactions on the above face are considerably more significant than those on the obverse 
face.  
 
EPR Studies of Ligand-Heme Interactions 
To investigate the interaction of one or more quinolines with the porphyrin, 
continuous-wave (CW) electron paramagnetic resonance (EPR) spectra (Figure 15) were 
recorded in order to investigate the spin state of the heme iron. The spectrum of heminii is 
typical of high spin ferric heme (S = 5/2) with turning points at geff = 6.0 and g‖ eff = 1.99. On 
addition of 4-fold molar excess of either 5-trans, 6-trans or 7a-trans under anaerobic 
conditions there was a dramatic ~65-95 % ±10 decrease in intensity of the ferric resonance 
without subsequent new signals. These observations suggest a change of iron spin state to an 
EPR silent species, possibly ferrous. This result clearly demonstrates for the first time that 
                                                          
ii
 Hemin chloride (hemin) is Fe(III)PPIX with a chloride ligand replacing the OH moiety. 
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binding allows a change of redox state in the porphyrin (Figure 14). The change of redox 
state of the heme was most pronounced for 5-trans followed by 6-trans, which was consistent 
with the relative antimalarial activity seen in vivo, on substituting the Cl with a CF3 group 
against Plasmodia. Further work is needed in the future to unambiguously determine the spin 
states, as well as the electron source.    
 
 
Figure 14. 9 GHz CW EPR spectra of a solution of 200 M hemin (black), hemin on manual 
5 sec mixing of 4-fold molar excess of 5-trans (green), 6-trans (red) and 7c-trans (blue). 
Hemin concentration was 200 M in all experiments. Inset shows magnification of the geff 
region. Spectra were recorded at 5 K, 100 kHz, 0.4 mT modulation amplitude, 1 mW, 1 scan. 
 
Implications for effective drug design 
 The results concerning the introduction of CF3 groups into positions 2 and 8 in 7c-
trans agreed with previously reported structure-activity correlations.[3, 7-8, 10-11, 23, 25c, 27-28, 66] 
Introduction of a CF3 group in position 7 proved to be superior in terms of antimalarial 
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activity over 2,7-di-trifluoromethyl substitution, which in turn is more active than 2,8-bis-
trifluromethylated-mono-4-aminoquinolines analogs.  
The interaction of the 2,8-trifluoromethyl bisquinoline with hematin falls into an 
anticipated order of stability from single crystal diffraction studies with hydrogen bonding[63] 
and covalent interactions dominating.[56b, 57-59] This evidence contradicts currently accepted 
models of drug antimalarial drug receptor interaction(s) since if the interactions between 
receptor and ligand were based on frequency of appearance in graphical forms then - 
depictions[22-23, 34n, 67] are most common and axial, covalent, coordinationed adducts[52, 56b, 57-
61]
 are fewer in number. Edge type interactions between drug and ligand are currently 
restricted to a few studies only.[62-63] Hence, - interactions are often assumed to be 
preferred orientation geometry[68] between drug and porphyrin but to our knowledge,  only 
one study compares the thermodynamics of a range of all three competing geometries,[62] 
which are essential for understanding antimalarial drug action.  
As indicated for quinoline methanols for covalent binding,[59] the complex, in which 
the drug coordinates via an axial Fe-O(alkoxide) bond, appears to be the most stable, but 
having measured the Raman spectra for 4-aminoquinolines such as metaquine 10[52] we 
previously failed to find convincing evidence of a Fe-N bond in solution as shown in Figure 
9. Consequently, the two forms favored by thermodynamic considerations, both covalent and 
edge type hydrogen bonding interactions, require re-investigations where their importance to 
antimalarial drug interactions with the receptor can be further clarified by a suitable 
spectrometric study taking into account the various forms of hematin and hemin suggested to 
account for antimalarial drug action.[3b, 3c, 5, 20-21, 23, 29, 56, 60-61, 63-65]  
 For bis-trifluoromethylquinolines, the - type interaction was less stable than the 
corresponding hydrogen bonded mode which favours interaction at the secondary amine 
rather than the sterically encumbered nitrogen buttressed between the trifluoromethyl groups 
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(See Figures 7 and  S15). This is consistent with sites of hydrogen bonding interactions seen 
both in solution by NMR (Figure 3) and in the solid state using crystallography.[23]  
 
Conclusion   
In conclusion, these results show that the inclusion of CF3 substituents has a major 
impact on the geometry of drug interaction with the antimalarial heme receptor. This may 
explain why the substituent pattern present in 1a is optimized for antimalarial activity only in 
the quinoline methanol class and this induces axial attack onto the porphyrin as verified 
recently by crystal structures.[59] Not only do the substituents affect the electronic properties 
of the molecule, they also offer alternative, preferential hydrogen bonding sites, and their 
steric bulk will reduce the possibility of interactions from the adjacent endocyclic nitrogen 
atom. Finally, both changes in redox state and geometry of binding to heme, when fully 
understood, could lead to the design of outstanding antimalarial drugs in vitro and in vivo. 
 
Experimental 
Solvents used in the reactions were purified according to standard methods. 63 All 
starting materials were of the highest purity available and were obtained from either the 
Aldrich Chemical Co., Lancaster Synthesis or Fluka. Chloroquine diphosphate was purchased 
from Sigma. Microanalyses were performed by MEDAC LTD, Brunel Science Centre, 
Egham, Surrey, UK and The Chemistry Department, University of Liverpool. Synthetic 
experiments were conducted using oven-dried glassware on a double vacuum manifold glass 
line under a protective atmosphere of dry argon. 
All materials, whether synthesized in this laboratory, or purchased, were continuously 
purified until they demonstrated a single peak by GC-NMR and NMR spectroscopy (19F and 
1H) to ensure that spectroscopic, physiochemical and pharmacological results were valid. 
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Melting points were determined using a Gallenkamp melting point apparatus and remain 
uncorrected but were verified by DSC.  
 Thin Layer Chromatography (TLC) was carried out on silica gel 60 glass backed 
plates using chloroform as eluant. Visualization was carried out either at 254 nm under UV 
light or in an iodine tank. Medium pressure chromatography was carried out using a custom 
made, one piece, all glass apparatus, foil covered packed with silica or neutral alumina (argon 
1-15 bar). See Supporting Information for further details and spectra. 
 
Spectroscopy  
NMR spectra were recorded on Bruker AC-250, Avance 300 (5 mm BBO probe head) 
and Bruker Ascend 600 MHz Ultrashield nuclear magnetic resonance spectrometers. 
Spectrometer frequencies (and internal standards) were: 1H: 250 MHz (TMS); 13C: 62.896 
MHz 19F: 235.36 MHz (CFC13) or 1H: 300.13 MHz (TMS); 13C: 75.468. Peak multiplicity 
and partial connectivity was deduced using a combination of DEPT, APT, HMQC and 1H- 
NMR experiments. DEPTQ experiment (16, 384 scans) was used to identify quaternary 
centers (see Supporting Information). Continuous-wave EPR spectra were recorded at 9.4 
GHz on a Bruker EMX spectrometer with a Super-high-Q rectangular cavity and an Oxford 
ESR-900 liquid helium cryostat. The operating conditions are stated on the Figure legends. 
  Mass spectrometry experiments were performed using a VG MICROMASS 7070H, 
operated at 70 eV electron energy [Source temperature 200-250 °C; Scan time 3 
seconds/decade from 750-720 Daltons (mass units)]. For chemical ionization (CI) 
experiments, the instrument was operated at 50 eV, and ammonia was used as the ionizing 
reagent. FT-IR spectroscopy was carried out using KBr discs on a GALAXY series 5000 FT-
IR spectrometer GL-7020. Electrospray experiments: Positive-ion electrospray mass 
spectrometry was performed using a Micromass model LCT TOF-MS with nitrogen as a 
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nebulization gas (Micromass Limited, Wythenshawe, Manchester, UK). UV spectra were 
measured using a Hewlett Packard HP8452A diode array spectrophotometer fitted with a 2 
mm path-length quartz cell. Fluorescence spectra were determined using a Varian Cary 
Eclipse® fluorescence spectrophotometer operating Cary Eclipse® software. HPLC: 
Chromatography was performed using a system comprising a Perkin Elmer PE250 isocratic 
pump, PE ISS200 autosampler and PE 235C diode-array detector. Chromatograms were 
collected, stored and processed using the Labsystems Ltd X-Chrom® chromatography data 
system. 
 
(±) trans-N,N2-bis-7-(trifluoromethyl-quinolin-4-yl) cyclohexane-1,2-diamine 6-trans  
Preparation using adaptation of a literature method[2a] produced a brown compound in 
quantitative yield. Suspension and vortexing in chloroform/ conc. NH3 for one hour, filtering 
at the pump and washing with chloroform (5 x 25 ml) at the pump produced a tan solid)[2b]; 
free base: m.p. 350.8 °C, DSC scan: 25 to 400 °C at 5.0 °C min-1). FT-IR cm-1: 3436 
(medium intensity, broadened N-H stretch); 1327 Amine γ (C-N) aromatic stretch.  
 
(±) trans-N1,N2-bis-(2,8-bis-trifluoromethyl-quinolin-4-yl) cyclohexane-1,2-diamine. 7c-
trans 
After recrystallization (x3) from acetone/HCl the dihydrochloride was a gray solid: m.p. > 
380 oC (decomposition). MS: (EI at 70 eV)) C25H20N4F12 640 Da. Detected, 640 (M+., 4 %), 
360 (M+. -F.,1 %), 360 (15 %), CF3+, 69 (8 %), 319 (6 %), 307 (5 %), 280 (5 %), 36 (100 
%). The dihydrochloride (100mg), was suspended in chloroform (100 ml) to which was 
added concentrated NH3 (33 % solution in water, 100 ml) and stirred then left for one week. 
The solution slowly deposited a mass of clear crystals. These were isolated by filtration then 
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slowly crystallized by diffusion of methanol into chloroform. Free base: m.p. 243.4 –245.2 
°C DSC: 0 ° C to 300 °C ramped at 10 °C min-1). 
 
1H NMR: H (300 MHz, DMSO-d6, 25 ºC):  = 1.49 (broad t, 2 H, 3J H ax-H ax = 9.48 Hz), 
1.77-1.89 (m, 4H), 2.06 (d, 2H, 3J H ax-H ax = 12.64 Hz), 4.00 (m, 2H), 7.16 (s, 2H, H-3), 7.37 
(t, 2H, H-6, 3J H-H = 7.92 Hz), 7.46 (broad d, 2 NH), 7.89 (d, H-5, 2H, 3J H-H = 7.20 Hz), 8.27 
(d, 3J H-H = 8.49 Hz). Methanol peak at 3.33 ppm (24 H). 13C NMR (75 MHz, 25 ºC, DMSO-
d6):   = 24.6 (C-3 CH2), 31.2 (C-2 CH2), 56.8 (C-1 CH), 95.1 (C-3’ CH), 123.7 (C-6’ CH), 
126.3 (C-5’ CH), 128.5 (C-7’ CH), 125.8 (C-8” quartet, 2J C-F = 29 Hz, 143.5 C-9’ 4 °C), 
147.3 (C-2” quartet, 2JC-F = 33 Hz), 152.0 (C-4 4 °C), 114.6-129.2 (2 distorted quartets, C-8’, 
C-2’, 2JC-F = ca. 114 and 110 Hz respectively). IR (Nujol) = 3436 (medium intensity, Sharp 
N-H stretch); 1315, 1292 cm-1 (strong 2° Amine γ (C-N), aromatic stretching vibration).  
 
Similarly, compounds 5, 6 and 7 were constructed according to published methods [2].  
 
Crystallography 
Crystal Data 7c-trans, C25H20F12N4O, M = 620.46, triclinic, a = 11.026(4), b = 
11.043(4), c = 12.808(4) Å,  = 93.963(4),  = 108.986(5),   =  92.591(5)o , U = 1467.3(9) 
Å3 , spacegroup P-1, dcalc  = 1.404 gcm-3, Z = 2. Data were measured with MoK radiation 
using the MARresearch Image Plate System The crystal was positioned at 70 mm from the 
Image Plate. 100 frames were measured at 2o intervals with a counting time of 2 mins. Data 
analysis was carried out with the XDS program 64 to provide 4816 independent reflections. 
The structure was solved using direct methods with the Shelx86 program. 65 Non-hydrogen 
atoms were refined with anisotropic thermal parameters. The hydrogen atoms bonded to 
carbon were included in geometric positions and given thermal parameters equivalent to 1.2 
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times those of the atom to which they were attached. The structure was refined on F2 using 
Shelxl 66 to R1 0.0832, wR2 0.1226 for 1821 reflections respectively with I>2(I). The data 
have been deposited at the Cambridge Crystallographic Data Centre with reference number 
CCDC 223083.  
 
UV Spectroscopic studies 
The UV spectra of the two compounds were determined over the range 190 – 800 nm 
on Thermo Scientific Evolution 300 spectrophotometer as described in the Supporting 
Information.  
 
Mass spectrometric studies[23] 
Samples were dissolved in a 1:1 (v/v) mixture of water and acetonitrile containing 
0.1% v/v of formic acid and diluted so as to yield approximately 3 μg/ml solutions. These 
were then each infused into the mass spectrometer at a rate of 3 μl/min, using a 250 μl glass 
syringe fitted into a Harvard Apparatus Model II syringe driver. Spectra were collected at a 
rate of 1 per second over a three minute period. For accurate mass determinations, a reference 
solution containing 10 μg/ml of Leucine-Enkephalin in acetonitrile/water/formic acid was 
infused at a rate of 3 μl/min into the Lockspray™ attachment using a second syringe. The 
analyte and reference streams were sampled at a rate of one spectrum per second over a three-
minute period and the spectra averaged. The MassLynx® software was used to adjust the 
average analyte spectrum on the basis of the observed base-peak mass of the average leucine-
enkaphalin spectrum, which has a nominal mass of 556.2771 Da. Instrumental operating 
conditions were factory standard with the following variable settings: Capillary: 2250V; 
Sample cone: 30V; Extraction cone: 10V; RF Lens: 1000V; Desolvation gas flow:638 L/min; 
Desolvation temperature: 150º C; Source temperature: 100ºC.  
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High performance liquid chromatographic studies 
Approximately 1.5 mg samples were shaken with 1.5 ml aliquots of the HPLC eluent 
and left to stand for several minutes before being centrifuged at 14,000 rpm for 1 min. A 1 ml 
aliquot of the supernatant was then transferred to a 2 ml autosampler vial, which was sealed 
and placed in the autosampler. The following instrumental conditions were employed: Eluent: 
0.1M KH2PO4/0.1M NaClO4 adjusted to pH 2.0 (HClO4): Acetonitrile (87:13 v/v) Flow rate: 
1.0 ml/min (approx. 1650 psi); Injection 10 μl; Column Phenomenex Lichrosphere 5CN, 
4.6 x 150 mm; Detection 254 nm. 
 
Antimalarial Efficacy [2] 
P. berghei N/13 (2107 parasitized erythrocytes) was inoculated intravenously (i.v.) 
in MF1 mice supplied by the Biological Services Unit, The University of Manchester, UK. 
Mice were housed in groups within plastic cages (length 38 cm  width 22 cm  height 
11cm) at room temperature (19-22C), on a 12h light (08:00-20:00) and 12h dark (20:00-
08:00) cycle, with unlimited access to food (CRM feeding pellets, SDS) and water. 
Experiments were licensed under the Animals (Scientific Procedures) Act 1986. In 
compliance with the conditions of the licence, infected mice were humanely killed when 
humane endpoints were reached. Parasitaemia was measured by counting Leishman-positive 
cells 72 h following infection using tail blood smears stained with Leishman’s reagent 
(Sigma Chemical Co., USA) 2 mg/ml methanol. Parasitaemia was calculated as the mean 
percentage (%)  SEM of erythrocytes containing Leishman-positive bodies for groups of 4 – 
8 mice for each dose tested. Drugs were delivered by the subcutaneous (s.c., 5 injections over 
72 h), intraperitoneal (i.p., 5 injections over 72 h) as described previously.[10-11] An 
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appropriate number of dose levels (2-8) were investigated for each compound, in order to 
determine the dose of drug (ID50) required to inhibit parasitaemia by 50% compared with 
parasitaemia in concurrent vehicle-treated mice. (±)-trans-N1,N2-bis-(7-chloroquinolin-4-
yl)cyclohexane-1,2-diamine 5-trans (ID50 = 3.0 mg/kg; 8.3mmol/kg) and the 7-
trifluoromethyl analogue 6-trans, (ID50 = 5.9 mg/kg; 14.9 mmol/kg) was active. However, the 
bistrifluoromethyl analog 7c-trans was inactive in vivo: there was no reduction in 
parasitaemia following 5 x doses of 10 and 50 mg/kg, compare with treated with vehicle 
treated animals (control parasitaemia: 65 %) Chloroquine diphosphate 4a was used as the 
control compound (ID50 = 4.3 mg/kg; 8.3 mmol/kg).  
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